# US 2026/0132177 A1 · Reelin compositions for treatment of neurological disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0132177 A1
- Document ID: US20260132177A1
- Status: Published application
- Kind: A1
- Application number: 19/387,230
- Filed: 2025-11-12
- Published: 2026-05-14
- Earliest claimed: 2016-08-03
- Assignees: University of South Florida
- Applicants: University of South Florida
- Inventors: Edwin J. Weeber
- Web page: https://patentgrep.com/patent/US20260132177A1

## CPC

- C07K 14/473: {alpha-Glycoproteins}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 35/761: Adenovirus
- A61K 38/1709: {from mammals}
- A61K 48/0066: {Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid}
- A61K 48/0075: {characterised by an aspect of the delivery route, e.g. oral, subcutaneous}
- A61K 48/0083: {characterised by an aspect of the administration regime}
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C07K 14/47: from mammals
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 15/62: DNA sequences coding for fusion proteins
- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- C07K 2319/00: Fusion polypeptide
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Changes in Reelin levels as well as Reelin signaling alter cognitive function. This can be accomplished by administering a therapeutically effective amount of a repeat fragment of Reelin, or a construct formed from fragment repeats of Reelin to a patient or subject. Changes to Reelin levels can be used to treat various neurodegenerative diseases, neuronal insults, or stroke, such as fragile X syndrome, William's syndrome, Rett syndrome, Down's syndrome, Angelman syndrome, autism, ischemia, hypoxia, Alzheimer's disease, and schizophrenia: Reelin can also be used to alter dendritic spine density, diminished long-term potentiation, and diminished synaptic plasticity and associative learning deficits. Constructs formed from repeat region 3 of full length Reelin and repeat region 5 of full length Reeling or repeat region 3 of full length Reelin and repeat region 6 of full length Reelin have been found particularly useful.

## Claims

### Claim at position 1

-18. (canceled)

### Claim 19

A method of treating a symptom of a nervous system disease or disorder in a patient, comprising administering to the patient a therapeutically effective amount of the viral vector composition encoding a Reelin recombinant protein fragment effective at inducing Reelin-dependent Apolipoprotein E Receptor (ApoER) activation and signaling, wherein the Reelin recombinant protein fragment is selected from:
Reelin fragment repeat R3 through R4,
Reelin fragment repeat R3 through R5,
Reelin fragment repeat R3 joined to Reelin fragment repeat R5 (SEQ ID NO:11),
or
Reelin fragment repeat R3 joined to Reelin fragment repeat R6 (SEQ ID NO: 9);
wherein
Reelin fragment repeat R3 is encoded by the nucleotide sequence consisting of SEQ ID NO: 2,
Reelin fragment repeat R4 is encoded by the nucleotide sequence consisting of SEQ ID NO: 3,
Reelin fragment repeat R5 is encoded by the nucleotide sequence consisting of SEQ ID NO: 4, and
Reelin fragment repeat R6 is encoded by the nucleotide sequence consisting of SEQ ID NO: 5; and wherein
a Loop Region encoded by a nucleotide sequence consisting of SEQ ID NO: 6 is disposed between Reelin fragment repeats R3 and R4, and a Loop Region encoded by a nucleotide sequence consisting of SEQ ID NO: 7 is disposed between Reelin fragment repeats R4 and R5.

### Claim 20 (depends on 19)

The method of claim 19, wherein the administration of the viral vector composition enhances dendritic spine density, long-term potentiation, synaptic plasticity, or learning deficits in the patient.

### Claim 21 (depends on 19)

The method of claim 19, wherein the therapeutically effective amount of the viral vector composition is administered to the patient intracerebrally by bilateral injection.

### Claim 22 (depends on 19)

The method of claim 19, wherein the viral vector is selected from the group consisting of AAV-9, AAV-5, AAV-4, and AAV-1.

### Claim 23 (depends on 19)

The method of claim 19, wherein the nervous system disorder is a neuropsychiatric disorder, a neurodegenerative disorder, a neuronal insult, a neuronal disorder, or a stroke.

### Claim 24 (depends on 19)

The method of claim 19, wherein the nervous system disease is Alzheimer's disease, Angelman syndrome, William's syndrome, Rett syndrome, Down's syndrome, autism, bipolar disorder, depression, schizophrenia, or a traumatic brain injury.

### Claim 25 (depends on 19)

The method of claim 19, wherein the nervous system disease is Fragile X Syndrome.
